Partner Content Partner Content VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.